Skip to main content

C. Diff clinical trials at UC Davis

4 research studies open to eligible people

Showing trials for
  • A Clinical Study of Experimental RBX2660 to Restore Healthy Gut Bacteria in People With Recurrent Clostridium Difficile Infection

    “This study involves an investigational new drug called RBX2660 (microbiota suspension), that may prevent your recurrent CDI.”

    open to eligible people ages 18 years and up

    This is a prospective, multicenter, randomized, double-blinded, placebo-controlled Phase 3 study of a microbiota suspension of intestinal microbes. Patients who have had at least one recurrence after a primary episode and have completed at least one round of standard-of-care oral antibiotic therapy or have had at least two episodes of severe CDI resulting in hospitalization within the last year may be eligible for the study. Subjects who are deemed failures following the blinded treatment per the pre-specified treatment failure definition may elect to receive an unblinded RBX2660 enema.

    Sacramento, California and other locations

  • A Study to Compare Experimental Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

    open to eligible people ages 18 years and up

    Summit is developing ridinilazole as a novel antimicrobial for Clostridium difficile Infection (CDI) with the goal of achieving comparable cure rates to standard of care, but reducing rates of recurrent disease. A phase 2 proof of concept study, with vancomycin as comparator, demonstrated these attributes with a comparable safety profile. A high fecal concentration of ridinilazole and little systemic exposure were noted. The rationale for this phase 3 study is to confirm the improvement in sustained clinical response of CDI over vancomycin and to compare the safety and tolerability of ridinilazole to that of vancomycin.

    Torrance, California and other locations

  • An Extension Study Testing Experimental "SER-109" in People With Recurrent Clostridium Difficile Infection (a bacteria the colon)

    “This is an Extension Study for ECOSPOR III study. You may qualify if you had a CDI recurrence prior to the week 8 study visit.”

    open to eligible people ages 18 years and up

    Cohort 1: Subjects who had a CDI recurrence in study SERES-012 within 8 weeks of receipt of study drug will be eligible. The purpose of this cohort is to assess safety and efficacy of SER-109 in reducing recurrence of Clostridioides difficile infection (CDI) in adults who had a CDI recurrence within 8 weeks after receipt of SER-109 or Placebo in study SERES-012. Cohort 2: Cohort 2 is an open-label program for subjects who were not part of SERES-012. The purpose of this cohort is to describe safety and tolerability of SER-109 in subjects 18 years of age or older with at least a first recurrence of CDI within the past 12 months.

    Butte, Montana and other locations

  • Experimental "SER-109" for the Treatment of Adults With Recurrent Clostridium Difficile Infection (bacteria in the colon)

    “Have you had Clostridium difficile infection (CDI) at least three times in the past 9 months?”

    open to eligible people ages 18 years and up

    Subjects will receive an oral dose of SER-109 in 4 capsules once daily for 3 consecutive days in Treatment Group I or matching placebo once daily for 3 consecutive days in Treatment Group II. The purpose of this study is to demonstrate the superiority of SER-109 vs placebo to reduce recurrence of CDI in adults up to 8 weeks after initiation of treatment.

    Sacramento, California and other locations

Last updated: